Trial Profile
Effects of Neprilysin Inhibition With ARNI (LCZ 696) on the Cardiorenal and Humoral Response to Acute Saline Volume Expansion in DM With and Without PDD
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- 22 Aug 2023 Planned number of patients changed from 72 to 80.
- 22 Aug 2023 Planned End Date changed from 31 Dec 2023 to 30 Jun 2024.
- 22 Aug 2023 Planned primary completion date changed from 31 Dec 2023 to 30 Jun 2024.